论文部分内容阅读
摘要目的非酒精性脂肪肝病(NAFLD)是西方国家最常见的肝脏疾病,目前尚无筛查非酒精性脂肪肝性肝炎(NASH)进展的成本效益的研究。方法在一般人群和筛选出的肥胖或糖尿病高危人群中,由第三方付款,运用无创性筛查策略进行年度的成本-效益分析。筛选使用成熟的研究技术,包括NAFLD纤维化评分、瞬时弹性成像(TE)和声学辐射冲击(ARFI)成像检测纤维化的进展(≥F3),以及通过血浆细胞角蛋白(CK)-18的检测来发现NAFLD。对比肝活检和MR
Abstract Objectives Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. There is no cost-benefit study to screen the progress of non-alcoholic steatohepatitis (NASH). Methods An annual cost-benefit analysis was conducted by a third party using non-invasive screening strategies among the general population and those at high risk of screening for obesity or diabetes. Screening for the development of fibrosis (≥F3) using well established research techniques including NAFLD fibrosis score, transient elastography (TE) and acoustic radiation shock (ARFI) imaging, and detection of plasma cytokeratin (CK) -18 To find NAFLD. Compare liver biopsy with MR